Država: Južnoafrička Republika
Jezik: engleski
Izvor: South African Health Products Regulatory Authority (SAHPRA)
Lennon
CILIFT 20 mg TABLETS SCHEDULING STATUS: S5 PROPRIETARY NAME (and dosage form): CILIFT 20 mg TABLETS COMPOSITION: Each tablet contains: Citalopram hydrobromide equivalent to 20 mg citalopram PHARMACOLOGICAL CLASSIFICATION: A 1.2 Psychoanaleptics (anti-depressants) PHARMACOLOGICAL ACTION: Citalopram, a bicyclic phthalone derivative, is a selective serotonin reuptake inhibitor (SSRI). It has an antidepressant effect. Citalopram selectively inhibits the reuptake of serotonin: It has no effect on the uptake of noradrenaline, dopamine or GABA. Citalopram and its metabolites have no antimuscarinic effects and are less cardiotoxic. Prevention of the reuptake of the monoamine transmitters serotonin potentiates their action in the brain, which appears to be associated with antidepressant activity. Citalopram is readily absorbed from the gastrointestinal tract and oral bioavailability is high (>80%) maximum plasma concentrations are reached within 4 hours (interval 1-6 hours) after oral administration. Citalopram is widely distributed throughout the body (the volume of distribution is ± 14 litres per kg). Steady state levels are obtained within 1 to 2 weeks. Protein binding is about 80%. Citalopram is metabolised by demethylation, deamination and oxidation to inactive metabolites. The elimination half-life of citalopram is reported to be about 36 hours (interval 28-42 hours ). It is excreted in the urine and faeces. Citalopram is distributed into breast milk in very low concentrations. INDICATIONS: CILIFT is indicated for the following: • Depression, and • Panic disorder with or without agoraphobia. CONTRA-INDICATIONS: • Hypersensitivity to CILIFT • Severe hepatic or renal failure (creatinine clearance of less than 20 mL/min). • Safely in pregnancy and lactation has not been established Pročitajte cijeli dokument